Jorgensen is set to testify before a Senate committee on Tuesday in a hearing focused on U.S. prices for its widely popular ...

The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

What the results might mean for the future of other developers in the cannabinoid receptor 1 (CB1) weight-loss arena came into question after Novo Nordisk A/S unveiled phase IIa findings with ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

It's the second lawsuit to be filed this year in Maine against insurance carriers that limit coverage of popular drugs like ...

Novo Nordisk braced for a congressional inquiry into the high prices of weight loss and diabetes drugs, particularly Ozempic, ...

An Australian women who's been using Ozempic to lose weight for more than a year has revealed whether it's worth the hype.

An Australian women who's been using Ozempic to lose weight for more than a year has revealed whether it's worth the hype.

Millions of older Americans with obesity could potentially get Medicare's help with the hefty price of a weight-loss medication in order to reduce ...

If confirmed, he would be the first person to serve in this position which was created in 2022. Novo Nordisk CEO Lars Jergensen testified on the company's pricing for its diabetes and weight loss ...

Lizzo is shutting down social media rumors while continuing to share her personal fitness journey. Recently she has lost a ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...